• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Harpoon Therapeutics Inc.

    2/13/24 5:06:13 PM ET
    $HARP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HARP alert in real time by email
    SC 13G 1 tv01077-harpoontherapeuticsi.htm SCHEDULE 13G harpoontherapeuticsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Harpoon Therapeutics Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  41358P205

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  41358P205

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    0

    7.  SOLE DISPOSITIVE POWER

    870,202

    8.  SHARED DISPOSITIVE POWER

    9,815

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    880,017

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.20%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Harpoon Therapeutics Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    611 Gateway Boulevard, Suite 400
    South San Francisco, CA 94080

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    41358P205

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $HARP alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $HARP

    DatePrice TargetRatingAnalyst
    1/5/2024$23.00Outperform
    Oppenheimer
    11/20/2023Outperform
    TD Cowen
    7/6/2022$16.00Buy
    Canaccord Genuity
    11/11/2021$25.00 → $19.00Outperform
    SVB Leerink
    9/28/2021$16.00Neutral → Buy
    Citigroup
    8/6/2021$29.00 → $25.00Outperform
    SVB Leerink
    More analyst ratings

    $HARP
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Merck & Co., Inc. bought $492,135,715 worth of shares (21,397,205 units at $23.00) (SEC Form 4)

      4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)

      3/11/24 3:27:05 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Leadership Updates

    Live Leadership Updates

    See more
    • Seismic Therapeutic Appoints Julie Eastland as Independent Board Director

      Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi

      9/23/24 8:00:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harpoon Therapeutics Strengthens Leadership Team

      James Bucher, J.D. joins as Chief Legal Officer Wendy Chang promoted to Chief People Officer SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced the appointment of James Bucher, J.D. as Chief Legal Officer, and the promotion of Wendy Chang, to Chief People Officer. Mr. Bucher and Ms. Chang are part of the executive management team and report directly to the Chief Executive Officer. "I am delighted to welcome Jim to the Harpoon leadership team and announce Wendy's promotion. I look forward to benefiting from Jim's extensive experience as we contin

      12/26/23 7:30:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harpoon Therapeutics Appoints Haibo Wang as Senior Vice President of Business Development

      SOUTH SAN FRANCISCO, Calif., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced the appointment of Haibo Wang as Senior Vice President of Business Development. Mr. Wang brings 15 years of biopharma business development, finance, and mergers and acquisitions (M&A) transaction experience to Harpoon. "We are pleased to welcome Haibo as Senior Vice President of Business Development at Harpoon," said Julie Eastland, President and CEO of Harpoon Therapeutics. "Haibo's extensive experience and strategic acumen will play a pivotal role in driving our business growth and forging impa

      8/1/23 7:30:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Harpoon Therapeutics with a new price target

      Oppenheimer initiated coverage of Harpoon Therapeutics with a rating of Outperform and set a new price target of $23.00

      1/5/24 8:28:33 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • TD Cowen initiated coverage on Harpoon Therapeutics

      TD Cowen initiated coverage of Harpoon Therapeutics with a rating of Outperform

      11/20/23 7:30:32 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Harpoon Therapeutics with a new price target

      Canaccord Genuity resumed coverage of Harpoon Therapeutics with a rating of Buy and set a new price target of $16.00

      7/6/22 9:26:38 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Harpoon Therapeutics Inc.

      SC 13G - Harpoon Therapeutics, Inc. (0001708493) (Subject)

      3/18/24 5:35:47 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)

      SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)

      3/13/24 4:14:35 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Harpoon Therapeutics Inc. (Amendment)

      SC 13D/A - Harpoon Therapeutics, Inc. (0001708493) (Subject)

      3/11/24 3:19:25 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New Leaf Biopharma Opportunities Ii, L.P. returned 1,859,169 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company (SEC Form 4)

      4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)

      3/11/24 5:28:46 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hunt Ronald was granted 424 shares, returned 1,872,393 shares to the company and returned 10,000 units of 8.000% Series A Redeemable Preferred Stock to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)

      3/11/24 5:26:33 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Silvernail Lauren P returned 5,000 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Harpoon Therapeutics, Inc. (0001708493) (Issuer)

      3/11/24 5:26:37 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    SEC Filings

    See more
    • SEC Form 15-12G filed by Harpoon Therapeutics Inc.

      15-12G - Harpoon Therapeutics, Inc. (0001708493) (Filer)

      3/21/24 4:00:56 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Harpoon Therapeutics Inc.

      EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)

      3/12/24 12:15:26 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Harpoon Therapeutics Inc.

      EFFECT - Harpoon Therapeutics, Inc. (0001708493) (Filer)

      3/12/24 12:15:11 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seismic Therapeutic Appoints Julie Eastland as Independent Board Director

      Seismic Therapeutic, Inc., the machine learning immunology company, today announced that Julie Eastland has been appointed as Independent Director to Seismic's Board. Ms. Eastland brings more than 30 years of experience in finance and strategy in clinical stage biotechnology companies delivering novel therapeutics to patients with unmet needs in oncology and immunology. "It is with much excitement that we welcome Julie to our Board of Directors. As a proven independent Director and executive with decades of experience in the biopharmaceutical industry, Julie brings deep knowledge across the company growth and drug development continuum, from discovery through commercialization," said Jo Vi

      9/23/24 8:00:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck Completes Acquisition of Harpoon Therapeutics, Inc.

      Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Harpoon Therapeutics, Inc. (NASDAQ:HARP). Harpoon is now a wholly-owned subsidiary of Merck, and Harpoon's common stock will no longer be publicly traded or listed on the Nasdaq Stock Market. "We continue to augment and diversify our oncology pipeline with innovative approaches to help people with cancer worldwide," said Dr. Dean Y. Li, president, Merck Research Laboratories. "We are ple

      3/11/24 8:15:00 AM ET
      $HARP
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

      Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (NASDAQ:HARP) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240108498651/en/ "At Merck, we continue to enhance our onc

      1/8/24 7:30:00 AM ET
      $HARP
      $MRK
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $HARP
    Financials

    Live finance-specific insights

    See more
    • Harpoon Therapeutics Presents Updated Interim Results at ASH 2022 for Novel T Cell Engager HPN217 in Relapsed/Refractory Multiple Myeloma

      Clinically active across a wide dose range (2.15 to 24 mg) in a Phase 1 trial of heavily pretreated patients with relapsed/refractory multiple myeloma77% (10/13) objective response rate (ORR) observed across highest doses (12 and 24 mg) Responses were durable, with many patients on treatment longer than a yearGenerally well-tolerated with a low incidence of cytokine release syndrome (CRS): Low-grade CRS in 29% of patients across highest step dose regimens; 95% of events occurred following first or second dose; no Grade 3 or higher CRS Dose and schedule optimization is ongoing; maximum tolerated dose not yet reached in step dose regimenManagement to host webcast and conference call to review

      12/11/22 10:00:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harpoon Therapeutics to Host HPN217 Interim Results and Corporate Update Call and Webcast on December 12, 2022

      SOUTH SAN FRANCISCO, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a conference call and webcast to review updated interim results of its Phase 1 HPN217 clinical program presented at the 64th American Society of Hematology (ASH) Annual Meeting and provide a corporate update. The live call/webcast will take place at 4:30 p.m. ET / 3:30 p.m. CT / 1:30 p.m. PT on December 12, 2022 and can be accessed by dialing 1-877-407-9039 for domestic callers and 1-201-689-8470 for international callers with conference ID code number 13734677. A webcast of the l

      12/5/22 7:30:00 AM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Harpoon Therapeutics Provides Pipeline Update for TriTAC® Clinical Programs and T Cell Engager Platforms

      Compelling initial clinical activity for HPN328 (DLL3) and HPN217 (BCMA) targeting programs observed in escalation phase of ongoing trialsEncouraging profile of tolerability and activity seen at higher doses in both HPN217 and HPN328; low grade CRS manageable, no Grade 3 CRS reported Interim data from the ongoing Phase 1/2 trial of HPN217 presented at the 2021 ASH Conference reported clinical activity at higher dose levels, including an overall response rate (ORR) of 63% and a disease control rate (DCR) of 88% in the HPN217 2150 µg/week cohort with a manageable safety profileIn the ongoing Phase 1/2 trial for HPN328, 3 out of 4 patients with small cell lung cancer (SCLC) in the two highest d

      12/13/21 4:05:00 PM ET
      $HARP
      Biotechnology: Pharmaceutical Preparations
      Health Care